Stratos Investment Management LLC Takes Position in AstraZeneca PLC (NASDAQ:AZN)

Stratos Investment Management LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,822 shares of the company’s stock, valued at approximately $250,000.

A number of other institutional investors also recently modified their holdings of the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in AstraZeneca during the third quarter worth $28,000. Ashton Thomas Securities LLC bought a new position in AstraZeneca during the third quarter worth $45,000. Albion Financial Group UT boosted its stake in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management boosted its stake in AstraZeneca by 38.4% during the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

Shares of AZN stock opened at $70.93 on Thursday. The firm has a 50-day moving average of $67.20 and a 200-day moving average of $73.72. The company has a market cap of $219.96 billion, a P/E ratio of 33.94, a P/E/G ratio of 1.18 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 earnings per share. Equities research analysts forecast that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on AZN shares. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, AstraZeneca has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.